Ionis

FDA approval
#AstraZeneca #FDA #hATTR amyloidosis #Ionis #Phase III trial

Wainua approval marks important milestone in amyloidosis treatment

AstraZeneca and Ionis’ Wainua (eplontersen) has been approved in the US for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults (hATTR-PN or ATTRv-PN). The approval by the US Food and Drug Administration (FDA) was based on the positive 35-week interim analysis from the… Read More

#News #Regulatory